Clovis Oncology, Inc.

OTCPK:CLVS.Q 株式レポート

時価総額:US$2.2m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Clovis Oncology マネジメント

マネジメント 基準チェック /34

Clovis Oncology's CEO is Patrick Mahaffy, appointed in Apr 2009, he has a tenure of 14.25 years. He directly owns 0.67% of the company’s shares, worth $14.56K. The average tenure of the management team and the board of directors is 7.4 years and 14.3 years respectively.`

主要情報

Patrick Mahaffy

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間14.3yrs
CEOの所有権0.7%
経営陣の平均在職期間7.4yrs
取締役会の平均在任期間14.3yrs

経営陣の近況

Recent updates

Clovis Oncology rises on clinical supply agreement with Isotopia

Sep 21

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Sep 12

Clovis Oncology: Needs Some Encouraging Data Quickly

Aug 11

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Aug 10
These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Clovis Oncology Q2 2022 Earnings Preview

Aug 05

EMA recommends restricted use of Clovis cancer drug

Jul 22

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Jul 08

Clovis: Shifting Toward Nuclear Medicine

Apr 25

Clovis Oncology: Forging A Fresh Perspective

Mar 31

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Feb 24
News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Jan 11

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Dec 30

Clovis Oncology Stock: Only Glimmers Of Hope

Oct 07

Clovis: Compelling With Upcoming Catalysts

Jul 30

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Jun 17
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Clovis Oncology and Inovio gain amid Reddit chatter

Jun 09

Clovis Oncology: Another Upcycle Coming

May 08

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

May 05

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Mar 17
Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 22
How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Jan 31

Clovis Oncology: Finally Green Shoots May Be On The Horizon

Jan 29

Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M

Jan 11

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Dec 31
What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial

Dec 29

Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study

Dec 21

Clovis Oncology existing holder purchases additional $7.5M convertible senior notes

Nov 25

Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance

Nov 09

Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term

Nov 06

Clovis Oncology EPS beats by $0.11, misses on revenue

Nov 05

CEO報酬分析

Clovis Oncology の収益と比較して、Patrick Mahaffy の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2022n/an/a

-US$252m

Jun 30 2022n/an/a

-US$263m

Mar 31 2022n/an/a

-US$258m

Dec 31 2021US$3mUS$739k

-US$265m

Sep 30 2021n/an/a

-US$299m

Jun 30 2021n/an/a

-US$310m

Mar 31 2021n/an/a

-US$336m

Dec 31 2020US$3mUS$721k

-US$369m

Sep 30 2020n/an/a

-US$370m

Jun 30 2020n/an/a

-US$385m

Mar 31 2020n/an/a

-US$413m

Dec 31 2019US$7mUS$719k

-US$400m

Sep 30 2019n/an/a

-US$400m

Jun 30 2019n/an/a

-US$396m

Mar 31 2019n/an/a

-US$377m

Dec 31 2018US$6mUS$689k

-US$368m

Sep 30 2018n/an/a

-US$321m

Jun 30 2018n/an/a

-US$291m

Mar 31 2018n/an/a

-US$366m

Dec 31 2017US$9mUS$636k

-US$346m

Sep 30 2017n/an/a

-US$365m

Jun 30 2017n/an/a

-US$370m

Mar 31 2017n/an/a

-US$324m

Dec 31 2016US$789kUS$224k

-US$349m

報酬と市場: Insufficient data to establish whether Patrick's total compensation is reasonable compared to companies of similar size in the US market.

報酬と収益: Patrick's compensation has been consistent with company performance over the past year.


CEO(最高経営責任者

Patrick Mahaffy (60 yo)

14.3yrs

在職期間

US$2,639,083

報酬

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Patrick Mahaffy
Co-Founder14.3yrsUS$2.64m0.67%
$ 14.6k
Daniel Muehl
Executive VP & CFO7.3yrsUS$1.19m0.072%
$ 1.6k
Paul Gross
Executive VP7.5yrsUS$1.20m0.068%
$ 1.5k
Lindsey Rolfe
Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer7.9yrsUS$1.24m0.078%
$ 1.7k
Thomas Harding
Executive VP & Chief Scientific Officer3.8yrsデータなしデータなし
Ann Bozeman
Executive Vice President of Human Resources6.8yrsデータなしデータなし

7.4yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: CLVS.Q's management team is seasoned and experienced (7.4 years average tenure).


取締役

名称ポジション在職期間報酬所有権
Patrick Mahaffy
Co-Founder14.3yrsUS$2.64m0.67%
$ 14.6k
Paul Klingenstein
Independent Director14.3yrsUS$260.00k0.041%
$ 889.9
Brian Atwood
Independent Director14.5yrsUS$270.00k0.040%
$ 875.1
Edward McKinley
Independent Director14.5yrsUS$270.00k0.17%
$ 3.8k
James Blair
Independent Director14.5yrsUS$270.00k0.044%
$ 953.2
Ginger Graham
Independent Chairman10.5yrsUS$287.50k0%
$ 0
Thorlef Spickschen
Independent Director14.5yrsUS$257.50k0.040%
$ 872.7
Ronit Simantov
Director2yrsUS$375.21kデータなし
Keith Flaherty
Independent Director10.5yrsUS$259.58k0%
$ 0
Richard Fair
Independent Director4.8yrsUS$257.50k0%
$ 0
Robert Azelby
Independent Director4.8yrsUS$255.00k0%
$ 0

14.3yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: CLVS.Q's board of directors are seasoned and experienced ( 14.3 years average tenure).